News & events
Subscribe
Receive Curasight news and market announcements.
Subscribe to receive Curasight press releases and company updates by email.
Subscribe to get the latest news first
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
I consent to Curasight handling my personal data. See Curasight's Terms of Use for information about how we handle personal data.
Seeing cancer. Treating cancer.
Curasight A/S is a clinical-stage radiopharmaceutical company developing products targeting uPAR, a target associated with aggressive cancer biology and a cancer target expressed across solid tumor types. The portfolio is organized through uTRACE®, the imaging and diagnostic platform, and uTREAT®, the therapeutic development platform comprising clinical stage glioblastoma programs and a next-generation uPAR-targeting ligand designed for modular alpha and beta payloads for additional solid tumor types.
Science
Investors
Investigational product statementTherapeutic product candidates within the uTRACE® and uTREAT® platform are investigational and they have currently not been approved for commercial use by any regulatory authority.
Forward-looking informationCertain information on this website may contain forward-looking statements regarding development plans, clinical milestones, regulatory activities, partnerships and other future events. Such statements involve risks and uncertainties, and actual outcomes may differ materially. Users should refer to Curasight’s latest market announcements and financial reports for current information.
Medical information statementInformation on this website is provided for general corporate and scientific information only and is not intended as medical advice. Patients should consult qualified healthcare professionals regarding diagnosis and treatment decisions.
+45 22 83 01 60 · info@curasight.com
Copyright 2026 © Curasight